| Drug Name |
Ubrogepant |
| Drug ID |
BADD_D02604 |
| Description |
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.[L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.[L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] remain in clinical development.[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative to its predecessors.[A189195] Several parenteral monoclonal antibodies acting against the CGRP pathway (e.g. [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207]
Compared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages.[A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular disease.[A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment of this debilitating condition. |
| Indications and Usage |
Ubrogepant is indicated for the acute treatment of migraine with or without aura in adults.[L10926] |
| Marketing Status |
approved; investigational |
| ATC Code |
N02CD04 |
| DrugBank ID |
DB15328
|
| KEGG ID |
D10673
|
| MeSH ID |
C000615620
|
| PubChem ID |
68748835
|
| TTD Drug ID |
D07GXR
|
| NDC Product Code |
0023-6499; 69037-0077; 0023-6501; 0023-6502; 0023-6498 |
| UNII |
AD0O8X2QJR
|
| Synonyms |
ubrogepant | ubrelvy | MK-1602 | 1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl)-2'-oxo-, (6S)- spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide |
